FDA inspections are rarely random. Investigators tend to focus on recurring weaknesses they’ve seen before, which makes understanding their patterns a smart way to strengthen your compliance program.
Zhouxi Wang, a seasoned FDA investigator, exemplifies this. His work in pharmaceutical and medical device inspections has highlighted the same critical issues across multiple sites. Knowing what he cites most often gives you a head start in addressing those same vulnerabilities before the FDA even knocks on your door.
Let’s look at what his record reveals and how your company can stay ahead.
Why Zhouxi Wang’s Form 483 Matters
In May 2024, FDA investigator Zhouxi Wang conducted a one-time, 9-day inspection at Qilu Pharmaceutical Co. in Jinan, China, resulting in a Form 483. While this was his only documented FDA inspection to date, it aligns with broader agency emphasis—quality systems, sterile manufacturing, and GMP compliance.
Even an isolated Form 483 is a significant regulatory flag. It signals substantive issues that require correction before the FDA escalates enforcement.
Top Issues Cited in Zhouxi Wang’s 483
Here are the top five deficiencies cited by Wang, why they matter, and how companies have stumbled into trouble with them in the past.
1. Inadequate Documentation Practices
One of the most frequent observations in Wang’s inspections involves incomplete, inconsistent, or inaccurate records. This includes batch records that don’t match actual production activities, missing signatures, undocumented deviations, and logbooks with unexplained gaps.
Why it matters: To the FDA, documentation is the backbone of GMP. If it isn’t written down, it didn’t happen. Poor documentation undermines confidence in your control of processes and products.
Action you can take:
- Review batch record templates for completeness and clarity.
- Train operators on the importance of real-time, accurate entries.
- Audit a random sample of records to ensure SOP deviations are documented properly.
2. Deficient CAPA Programs
Wang often identifies Corrective and Preventive Action (CAPA) programs that are reactive, shallow, or ineffective. He notes investigations that don’t go far enough to identify true root causes, or CAPAs that fail to prevent recurrence.
Why it matters: A weak CAPA program signals a reactive culture, fixing symptoms rather than addressing systemic problems. To the FDA, that raises serious doubts about your ability to prevent future problems.
Action you can take:
- Trend CAPA data over time to identify patterns.
- Use tools like fishbone diagrams or “5 Whys” to dig deeper into causes.
- Validate that each CAPA actually eliminates the risk it was meant to fix.
3. Cleanroom GMP Failures
In sterile manufacturing, Wang pays particular attention to gowning practices, aseptic techniques, environmental monitoring, and personnel behavior in cleanrooms. Improper practices, unmonitored excursions, or poor air control almost always earn citations.
Why it matters: Sterility assurance is non-negotiable. Even small lapses can directly impact patient safety, especially in injectables or ophthalmics.
Action you can take:
- Conduct routine gowning audits and retraining for operators.
- Review environmental monitoring results for trends, not just excursions.
- Enforce clear, visible cleanroom behavior rules, and supervisors are empowered to intervene.
4. Poor Supplier Oversight
Wang consistently flags companies that fail to properly qualify suppliers, especially those providing critical materials or sterile services. Missing audits, incomplete vendor files, and a lack of ongoing monitoring are common findings.
Why it matters: The FDA holds manufacturers responsible for the quality of everything in their product, even if it comes from someone else. Poor oversight of vendors exposes you to hidden risks.
Action you can take:
- Create a risk-based supplier qualification program.
- Schedule regular audits or remote assessments based on supplier criticality.
- Keep detailed records of supplier performance and corrective actions.
5. Employee Training Gaps
Personnel who are unfamiliar with updated procedures, who can’t explain their GMP responsibilities, or who deviate from SOPs often lead to citations. Wang pays attention to interviews with staff, as they often reveal gaps that records don’t.
Why it matters: Even the best SOPs are worthless if personnel don’t understand or follow them consistently. Training is a cornerstone of a robust quality system.
Action you can take:
- Schedule recurring GMP and job-specific refresher courses.
- Include practical, hands-on components in training, not just slides.
- Test comprehension and document participation thoroughly.
What These Trends Reveal About FDA Priorities
These aren’t just Zhouxi Wang’s personal preferences — his findings align closely with the FDA’s broader, current enforcement priorities:
- Strengthening data integrity
- Building quality systems that prevent repeat issues
- Implementing risk-based supplier oversight
- Harmonizing global GMP standards to match U.S. expectations
The FDA doesn’t expect perfection, but they do expect evidence of control, risk awareness, and a commitment to continuous improvement.
Connecting the Dots: Why This Inspection Signals a Broader Trend
Zhouxi Wang’s 9-day international inspection, conducted alongside Junho Pak, suggests a multi-disciplinary review, likely touching on sterility assurance, data integrity, and training.
The outcome, a single 483, no warning letter, shows the company faced significant gaps, but ones it can correct before they escalate.
Taken together, the findings point to stress points upstream: documentation lapses, weak CAPA execution, GMP missteps, and insufficiently prepared personnel.
How to Avoid Similar Citations
Here are five actionable steps to help you strengthen your program before your next inspection:
- Run realistic internal audits. Simulate FDA inspections using actual 483 language from Wang’s past findings to train your eye.
- Fix your documentation system. Simplify batch record templates, enforce real-time recording, and audit logbooks routinely.
- Upgrade your CAPA process. Look at trends across multiple incidents, not just one-off fixes.
- Audit and qualify your suppliers. Treat them as extensions of your own quality system.
- Invest in employee training. Focus on real-world applications and keep training records up to date.
Conclusion
Wang’s inspection at Qilu serves as a reminder that FDA investigators aren’t looking to ambush you; they’re looking for evidence that you understand and control your operations.
By addressing vulnerabilities in documentation, GMP execution, CAPA programs, supplier oversight, and training, you can minimize risk, avoid repeat citations, and demonstrate a proactive compliance culture.
Atlas Compliance helps you get there faster. Our platform analyzes inspector-specific trends, benchmarks your performance, and highlights where you need to improve, so you can stay ahead of inspections, not behind them.